IL201963A - Vectors for multi-gene expression, host cell and pharmacy preparation containing and using them - Google Patents
Vectors for multi-gene expression, host cell and pharmacy preparation containing and using themInfo
- Publication number
- IL201963A IL201963A IL201963A IL20196309A IL201963A IL 201963 A IL201963 A IL 201963A IL 201963 A IL201963 A IL 201963A IL 20196309 A IL20196309 A IL 20196309A IL 201963 A IL201963 A IL 201963A
- Authority
- IL
- Israel
- Prior art keywords
- nucleic acid
- pharmaceutical composition
- host cell
- vectors
- gene expression
- Prior art date
Links
- 239000013598 vector Substances 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 230000014509 gene expression Effects 0.000 title 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 5
- 102000039446 nucleic acids Human genes 0.000 abstract 5
- 108020004707 nucleic acids Proteins 0.000 abstract 5
- 239000002773 nucleotide Substances 0.000 abstract 2
- 125000003729 nucleotide group Chemical group 0.000 abstract 2
- 230000003449 preventive effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/863—Poxviral vectors, e.g. entomopoxvirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07360019 | 2007-05-15 | ||
| PCT/EP2008/051031 WO2008138648A1 (en) | 2007-05-15 | 2008-01-29 | Vectors for multiple gene expression |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL201963A0 IL201963A0 (en) | 2011-08-01 |
| IL201963A true IL201963A (en) | 2013-09-30 |
Family
ID=39522406
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL201963A IL201963A (en) | 2007-05-15 | 2009-11-05 | Vectors for multi-gene expression, host cell and pharmacy preparation containing and using them |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US8337859B2 (https=) |
| EP (1) | EP2162544B1 (https=) |
| JP (1) | JP5474767B2 (https=) |
| KR (1) | KR101514473B1 (https=) |
| CN (1) | CN101688223B (https=) |
| AR (1) | AR065075A1 (https=) |
| AU (1) | AU2008250520B2 (https=) |
| BR (1) | BRPI0810305A2 (https=) |
| CA (1) | CA2686772C (https=) |
| ES (1) | ES2416361T3 (https=) |
| IL (1) | IL201963A (https=) |
| MX (1) | MX2009012272A (https=) |
| PE (1) | PE20090483A1 (https=) |
| RU (1) | RU2462513C2 (https=) |
| TW (1) | TW200844231A (https=) |
| WO (1) | WO2008138648A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8415462B2 (en) | 2007-05-15 | 2013-04-09 | Transgene S.A. | Signaling peptides |
| WO2010085660A2 (en) * | 2009-01-23 | 2010-07-29 | Roger Williams Hospital | Viral vectors encoding multiple highly homologous non-viral polypeptides and the use of same |
| TWI555531B (zh) * | 2009-08-07 | 2016-11-01 | 傳斯堅公司 | 用以治療ｂ型肝炎病毒（ｈｂｖ）感染之組成物 |
| WO2011127924A2 (de) * | 2010-04-16 | 2011-10-20 | Charité - Universitätsmedizin Berlin | Mittel zur lokalen behandlung von zervixdysplasien |
| GB201016471D0 (en) * | 2010-09-30 | 2010-11-17 | Isis Innovation | Viral vector immunogenic compositions |
| US9216213B2 (en) * | 2011-04-20 | 2015-12-22 | Merial, Inc. | Adjuvanted rabies vaccine with improved viscosity profile |
| ES2646590T3 (es) * | 2012-01-24 | 2017-12-14 | Sanford Health | Polinucleótidos para el tratamiento de tumores positivos para polipéptidos víricos oncogénicos |
| CA2901501C (en) | 2013-02-21 | 2023-03-07 | Children's Hospital Of Eastern Ontario Research Institute Inc. | Vaccine composition |
| SG10201903349YA (en) * | 2014-10-14 | 2019-05-30 | Univ Pennsylvania | Recombinant listeria vaccine strains and methods of using the same in cancer immunotherapy |
| JP2019505512A (ja) | 2016-01-08 | 2019-02-28 | バッシボディ アクスイェ セルスカプ | 治療用抗癌ネオエピトープワクチン |
| EP3452087A1 (en) * | 2016-05-02 | 2019-03-13 | Janssen Vaccines & Prevention B.V. | Therapeutic hpv vaccine combinations |
| EP3518966A1 (en) | 2016-09-29 | 2019-08-07 | GlaxoSmithKline Biologicals S.A. | Compositions and methods of treatment of persistent hpv infection |
| EP3461497A1 (en) * | 2017-09-27 | 2019-04-03 | GlaxoSmithKline Biologicals S.A. | Viral antigens |
| CA3120715A1 (en) * | 2018-11-21 | 2020-05-28 | Mayo Foundation For Medical Education And Research | Adenoviruses and methods for using adenoviruses |
| KR20240086779A (ko) * | 2022-12-05 | 2024-06-19 | 경상국립대학교산학협력단 | 다중 단백질의 발현을 위한 신규 핵산 구조체 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9105383D0 (en) * | 1991-03-14 | 1991-05-01 | Immunology Ltd | An immunotherapeutic for cervical cancer |
| DE69828284T2 (de) | 1997-06-30 | 2005-12-08 | Nippon Kayaku K.K. | Naphthyridinderivate oder salze davon |
| FR2766091A1 (fr) | 1997-07-18 | 1999-01-22 | Transgene Sa | Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee |
| FR2774699B1 (fr) | 1997-11-17 | 2003-10-03 | Rhone Poulenc Rorer Sa | Methode de reduction des evenements de recombinaison homologue |
| US7001995B1 (en) * | 1999-08-25 | 2006-02-21 | Merck & Co., Inc. | Synthetic human papillomavirus genes |
| AU772611B2 (en) * | 1999-08-25 | 2004-05-06 | Merck Sharp & Dohme Corp. | Synthetic human papillomavirus genes |
| US20050118139A1 (en) | 2001-08-23 | 2005-06-02 | Lingyi Huang | Vaccine using papilloma virus e proteins delivered by viral vector |
| CN102703393A (zh) * | 2002-05-16 | 2012-10-03 | 巴法里安诺迪克有限公司 | 表达插入痘病毒基因组中的同源基因的重组痘病毒 |
| WO2008092854A2 (en) * | 2007-01-30 | 2008-08-07 | Transgene S.A. | Papillomavirus e2 polypeptide used for vaccination |
-
2008
- 2008-01-29 JP JP2010507858A patent/JP5474767B2/ja not_active Expired - Fee Related
- 2008-01-29 CN CN200880016061XA patent/CN101688223B/zh not_active Expired - Fee Related
- 2008-01-29 CA CA2686772A patent/CA2686772C/en not_active Expired - Fee Related
- 2008-01-29 TW TW097103228A patent/TW200844231A/zh unknown
- 2008-01-29 US US12/599,971 patent/US8337859B2/en not_active Expired - Fee Related
- 2008-01-29 ES ES08708348T patent/ES2416361T3/es active Active
- 2008-01-29 WO PCT/EP2008/051031 patent/WO2008138648A1/en not_active Ceased
- 2008-01-29 RU RU2009144898/10A patent/RU2462513C2/ru active
- 2008-01-29 AR ARP080100356A patent/AR065075A1/es not_active Application Discontinuation
- 2008-01-29 MX MX2009012272A patent/MX2009012272A/es active IP Right Grant
- 2008-01-29 PE PE2008000210A patent/PE20090483A1/es not_active Application Discontinuation
- 2008-01-29 BR BRPI0810305A patent/BRPI0810305A2/pt not_active Application Discontinuation
- 2008-01-29 KR KR1020097023308A patent/KR101514473B1/ko not_active Expired - Fee Related
- 2008-01-29 EP EP08708348.1A patent/EP2162544B1/en not_active Not-in-force
- 2008-01-29 AU AU2008250520A patent/AU2008250520B2/en not_active Ceased
-
2009
- 2009-11-05 IL IL201963A patent/IL201963A/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| EP2162544B1 (en) | 2013-04-17 |
| RU2462513C2 (ru) | 2012-09-27 |
| CA2686772A1 (en) | 2008-11-20 |
| TW200844231A (en) | 2008-11-16 |
| KR101514473B1 (ko) | 2015-04-22 |
| MX2009012272A (es) | 2009-12-01 |
| HK1135731A1 (en) | 2010-06-11 |
| ES2416361T3 (es) | 2013-07-31 |
| US20100303838A1 (en) | 2010-12-02 |
| EP2162544A1 (en) | 2010-03-17 |
| US8337859B2 (en) | 2012-12-25 |
| CA2686772C (en) | 2015-03-24 |
| AU2008250520A1 (en) | 2008-11-20 |
| WO2008138648A1 (en) | 2008-11-20 |
| AU2008250520B2 (en) | 2013-10-31 |
| AR065075A1 (es) | 2009-05-13 |
| CN101688223B (zh) | 2013-07-31 |
| JP5474767B2 (ja) | 2014-04-16 |
| KR20100019432A (ko) | 2010-02-18 |
| CN101688223A (zh) | 2010-03-31 |
| IL201963A0 (en) | 2011-08-01 |
| BRPI0810305A2 (pt) | 2018-07-10 |
| PE20090483A1 (es) | 2009-05-20 |
| RU2009144898A (ru) | 2011-06-20 |
| JP2010526547A (ja) | 2010-08-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL201963A (en) | Vectors for multi-gene expression, host cell and pharmacy preparation containing and using them | |
| NZ587105A (en) | Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage | |
| MY156855A (en) | Novel regulatory elements | |
| MX2020003092A (es) | Vectores de adn no integrantes para la modificacion genetica de celulas. | |
| MX2014001070A (es) | Gen plaguicida axmi279 y sus metodos de uso. | |
| MX2014007233A (es) | Composiciones de nucleosidos, nucleotidos y acidos nucleicos modificados. | |
| MX2012000202A (es) | Gen plaguicida axmi-205 y metodos para su uso. | |
| BR112012020705A2 (pt) | axmi221z, axmi222z, axmi224z, e axmi225z genes de delta-endotoxina e métodos para sua utilização. | |
| MX2014000993A (es) | Gen de la toxina axmi270 y sus metodos de uso. | |
| MX357562B (es) | Axmi-115, axmi-113, axmi-005, axmi-163 y axmi-184: proteinas insecticidas vip3a de bacillus thuringiensis y metodos para su uso. | |
| MX2011003229A (es) | Terapia genica con porfobilinogeno desaminasa. | |
| NZ603348A (en) | Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof | |
| EA201170717A1 (ru) | Дельта-эндотоксиновый ген axmi-150 и способы его применения | |
| UA115236C2 (uk) | Ген дельта-ендотоксину axmi345 та спосіб його застосування | |
| MX2009000656A (es) | Acidos nucleicos que se fijan a sdf-i. | |
| MY175477A (en) | Variant aav and compositions, methods and uses for gene transfer to cells, organs and tissues | |
| NZ603901A (en) | Vectors and sequences for the treatment of diseases | |
| MX2007009206A (es) | Axmi-018, axmi-020 y axmi-021, una familia de genes de delta-endotoxina y metodos para su uso. | |
| MX2010003371A (es) | Constructos interruptores genicos terapeuticos y biorreactores para la expresion de moleculas bioterapeuticas y usos de los mismos. | |
| MX351526B (es) | Proteinas variantes axmi205 y sus metodos de uso. | |
| GB201201178D0 (en) | Novel enzymes | |
| HK1198170A1 (en) | Pseudomonas exotoxin a with less immunogenic b cell epitopes | |
| NZ715007A (en) | Nucleic acid molecules that target the vacuolar atpase c subunit and confer resistance to coleopteran pests | |
| BRPI0806252A2 (pt) | molécula de ácido nucléico de promotor, vetor recombinante, célula de hospedeiro e método de expressão de gene alvo | |
| NZ700902A (en) | Lowering saturated fatty acid content of plant seeds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed |